Decisions regarding the optimal treatment of acute myelogenous leukemia in the elderly patient requires the consideration of multiple factors. Population-based studies have demonstrated that, for all age groups, aggressive therapy results in improved survival and quality of life when compared with palliative care.
http://asheducationbook.hematologylibrary.org/content/2010/1/62.full
Factors that may increase your risk of acute myelogenous leukemia include: 1  Increasing age. 2  Your sex. 3  Previous cancer treatment.  Exposure to 1  radiation. Dangerous chemical exposure. 2  Smoking. Other blood disorders.  Genetic disorders.
http://www.mayoclinic.org/diseases-conditions/acute-myelogenous-leukemia/basics/risk-factors/con-20043431
Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Leukemia may affect red blood cells, white blood cells, and platelets. There are different subtypes of AML.
https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq/
Acute myeloid leukemia (AML) is generally divided into prognostic subgroups based primarily on cytogenetic alterations, with further refinement based on a small group of molecular markers, and the presence of morphologically identifiable residual disease after treatment.1 Half of AML cases in young adult patients fall into the standard-risk subgroup ...
http://www.hematology.org/Thehematologist/Diffusion/5474.aspx
Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. This type of cancer usually gets worse quickly if it is not treated.
https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq/
Clinicians were informed of the results of MRD testing in this group. This analysis confirmed the association of MRD with a significantly worse outcome at two years due to increased incidence of relapse (70% vs. 31%; p=0.001) and lower rate of overall survival (40% vs. 87%; p=0.001).
http://www.hematology.org/Thehematologist/Diffusion/5474.aspx
Acute myeloid leukemia (AML) presents at all ages, but is mainly a disease of the elderly, with a median age of 69 years in the white US population. In the Swedish Acute Leukemia Registry, 68% of patients diagnosed with AML since 1973 were over age 60 years; between 1997 and 2005, 75% was aged 60 years or more.
http://asheducationbook.hematologylibrary.org/content/2010/1/62.full
Acute myeloid leukemia (AML), also known as acute nonlymphocytic leukemia, represents a group of clonal hematopoietic stem cell disorders in which both a block in differentiation and unchecked proliferation result in the accumulation of myeloblasts at the expense of normal hematopoietic precursors.
http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology-oncology/acute-myelogenous-leukemia/
Statistics at a GlanceShow More. At a Glance. Number of New Cases and Deaths per 100,000: The number of new cases of acute myeloid leukemia was 4.2 per 100,000 men and women per year. The number of deaths was 2.8 per 100,000 men and women per year. These rates are age-adjusted and based on 2010-2014 cases and deaths.
https://seer.cancer.gov/statfacts/html/amyl.html
The incidence rate of AML increases with age. In the United States, the median age of patients with AML is 67 years. The age-adjusted population incidence is 12.2 per 100,000 for people older than 65 years, compared with 1.3 per 100,000 for those younger than 65 years.
http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology-oncology/acute-myelogenous-leukemia/
acute myelogenous leukemia age
Acute myeloid leukemia presents at all ages, but is mainly a disease of the elderly, with a median age of 69 years in the white United States population.